Accuray's Cancer Treatment Device CyberKnife To Expand In Japanese Market
This article was originally published in PharmAsia News
Executive Summary
With Japan's Ministry of Health, Labor and Welfare approval of CyberKnife, a cancer treatment device made by U.S. medical device maker Accuray in June, the device has been expanded from treating head and neck tumors to lung, liver, kidney, prostate and other cancers. Using image guidance technology and computer controlled robotics, the CyberKnife reduces necessary treatments from 50-70 times to only 5 times, and patients suffer less due to its painless nature and no need for anesthesia. Costing ¥600 million per unit, Accuray Japan President Mineo Kinashi said the company will apply for more insurance coverage for the treatment, and estimated that the market will increase from its current 20 units to 100 units in five years. (Click here for more - Japanese language